Arrowhead Pharmaceuticals Yönetim
Yönetim kriter kontrolleri 3/4
Arrowhead Pharmaceuticals CEO'su Chris Anzalone, Dec2007 tarihinde atandı, in görev süresi 16.92 yıldır. in toplam yıllık tazminatı $ 9.92M olup, şirket hissesi ve opsiyonları dahil olmak üzere 9.1% maaş ve 90.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 2.99% ine doğrudan sahiptir ve bu hisseler $ 79.28M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 6.4 yıl ve 14 yıldır.
Anahtar bilgiler
Chris Anzalone
İcra Kurulu Başkanı
US$9.9m
Toplam tazminat
| CEO maaş yüzdesi | 9.1% |
| CEO görev süresi | 16.9yrs |
| CEO sahipliği | 3.0% |
| Yönetim ortalama görev süresi | 6.4yrs |
| Yönetim Kurulu ortalama görev süresi | 14yrs |
Son yönetim güncellemeleri
Recent updates
Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) A Risky Investment?
Oct 04
Arrowhead Pharmaceutical: Driving To Commercialization
Jul 26Estimating The Fair Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Jun 12Arrowhead Pharmaceuticals: Hoping Something Sticks
May 27Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Too Much Debt?
May 21Arrowhead Pharmaceuticals: Focus Turns To Upcoming Pipeline Inflection Point
May 17Some Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shareholders Look For Exit As Shares Take 27% Pounding
Apr 03Arrowhead: RNAi Specialist Struggling To Show A Strong Hand (Rating Downgrade)
Mar 30Shareholders May Be Wary Of Increasing Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package
Mar 08Estimating The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Feb 19Arrowhead Pharmaceuticals: A Leading Small-Cap Developer Of RNAi Therapy
Jan 21Pinning Down Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) P/S Is Difficult Right Now
Dec 25Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Debt In A Risky Way?
Sep 19Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Climb 25% But Its Business Is Yet to Catch Up
Apr 17Shareholders May Be More Conservative With Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation For Now
Mar 10A Look At The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Jan 24We're Not Worried About Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Cash Burn
Oct 24Arrowhead Pharmaceuticals: Emerging From The 'Data Desert' With A Flood Of Opportunities
Sep 12Johnson & Johnson And Arrowhead Pharmaceuticals Could Have Big News Coming
Aug 23Arrowhead seeks New Zealand regulator nod to start trial of ARO-MMP7 for lung disease
Aug 17Arrowhead Pharmaceuticals: An RNAi Name To Know
Jul 28Arrowhead Pharmaceuticals names internal officer as new COO
Jul 20Arrowhead begins dosing in early-stage studies of 2 potential lung disease drugs
Jul 05Arrowhead Pharma: We Can Afford To Wait For More Proof
Jun 28CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$539m |
| Mar 31 2024 | n/a | n/a | -US$471m |
| Dec 31 2023 | n/a | n/a | -US$297m |
| Sep 30 2023 | US$10m | US$903k | -US$205m |
| Jun 30 2023 | n/a | n/a | -US$181m |
| Mar 31 2023 | n/a | n/a | -US$150m |
| Dec 31 2022 | n/a | n/a | -US$155m |
| Sep 30 2022 | US$12m | US$863k | -US$176m |
| Jun 30 2022 | n/a | n/a | -US$154m |
| Mar 31 2022 | n/a | n/a | -US$112m |
| Dec 31 2021 | n/a | n/a | -US$183m |
| Sep 30 2021 | US$25m | US$837k | -US$141m |
| Jun 30 2021 | n/a | n/a | -US$126m |
| Mar 31 2021 | n/a | n/a | -US$110m |
| Dec 31 2020 | n/a | n/a | -US$103m |
| Sep 30 2020 | US$14m | US$786k | -US$85m |
| Jun 30 2020 | n/a | n/a | -US$24m |
| Mar 31 2020 | n/a | n/a | US$10m |
| Dec 31 2019 | n/a | n/a | US$53m |
| Sep 30 2019 | US$2m | US$674k | US$68m |
| Jun 30 2019 | n/a | n/a | US$46m |
| Mar 31 2019 | n/a | n/a | US$10m |
| Dec 31 2018 | n/a | n/a | -US$29m |
| Sep 30 2018 | US$2m | US$643k | -US$54m |
Tazminat ve Piyasa: Chris 'nin toplam tazminatı ($USD 9.92M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 6.60M ).
Tazminat ve Kazançlar: Chris 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Chris Anzalone (55 yo)
16.9yrs
Görev süresi
US$9,918,093
Tazminat
Dr. Christopher R. Anzalone, also known as Chris, Ph D., has been the Chief Executive Officer and President at Arrowhead Pharmaceuticals, Inc. since December 1, 2007. He serves as Chief Executive Officer o...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO, President & Director | 16.9yrs | US$9.92m | 2.99% $ 79.3m | |
| Chief Financial Officer | 14.8yrs | US$3.12m | 0.19% $ 5.0m | |
| COO, General Counsel & Secretary | 9.9yrs | US$3.31m | 0.23% $ 6.1m | |
| Chief of Discovery & Translational Medicine | no data | US$3.05m | 0.16% $ 4.4m | |
| Founder and Founder & Director of Insert Therapeutics Inc & Calando | no data | Veri yok | Veri yok | |
| Head of Investor Relations & VP | no data | Veri yok | Veri yok | |
| Director of Communications | 19.3yrs | Veri yok | Veri yok | |
| Chief Medical Scientist | less than a year | US$16.34m | Veri yok | |
| Head of Toxicology & VP | no data | Veri yok | Veri yok | |
| Chief Commercial Officer | 2.4yrs | US$2.97m | 0.013% $ 357.1k | |
| Head of Tax | 2.8yrs | Veri yok | Veri yok | |
| VP & Treasurer | 2.8yrs | Veri yok | Veri yok |
6.4yrs
Ortalama Görev Süresi
60yo
Ortalama Yaş
Deneyimli Yönetim: ARWR 'un yönetim ekibi deneyimli ve deneyimlidir ( 6.4 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO, President & Director | 16.9yrs | US$9.92m | 2.99% $ 79.3m | |
| Founder and Founder & Director of Insert Therapeutics Inc & Calando | no data | Veri yok | Veri yok | |
| Chairman of the Board | 14yrs | US$474.60k | 0.11% $ 3.0m | |
| Independent Lead Director | 12.9yrs | US$459.60k | 0.074% $ 2.0m | |
| Independent Director | 6.8yrs | US$469.60k | 0.026% $ 701.7k | |
| Member of Hepatitis B Clinical Advisory Board | no data | Veri yok | Veri yok | |
| Chairman of Hepatitis B Clinical Advisory Board | no data | Veri yok | Veri yok | |
| Independent Director | 14.3yrs | US$459.60k | 0.037% $ 977.1k | |
| Member of Alpha-1 Antitrypsin Deficiency Clinical Advisory Board | no data | Veri yok | Veri yok | |
| Member of Hepatitis B Clinical Advisory Board | no data | Veri yok | Veri yok | |
| Member of Hepatitis B Clinical Advisory Board | no data | Veri yok | Veri yok | |
| Member of Hepatitis B Clinical Advisory Board | no data | Veri yok | Veri yok |
14.0yrs
Ortalama Görev Süresi
65yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: ARWR 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 14 yıldır).